The Medicine Maker recently published an in-depth interview with Dr. Igor Fisch, exploring the practical implications of long-term innovation in biotechnology and the challenges of translating scientific progress into measurable real-world outcomes.
04/16/2025 --- In a recent interview with Rob Coker, Deputy Editor at The Medicine Maker, NewBiologix CEO, Igor Fisch, shared his insights on the future of gene therapy, the challenges in manufacturing, and the exciting potential of scalable gene therapy solutions.
In this conversation, Igor discusses his journey from academic science to biotech entrepreneurship, emphasizing the transformative potential of gene therapy. Fisch, who previously co-founded Selexis, is now tackling one of gene therapy’s biggest challenges: scalable and cost-effective manufacturing. At NewBiologix, he aims to replace traditional AAV production methods with stable cell lines, offering more consistency and affordability. He also highlights the importance of fostering scientific talent, maintaining work-life balance, and his belief that solving manufacturing bottlenecks will unlock broader access to advanced therapies.
